I definitely wondered the same Epichemist, expect most things to fail in the TBI/CVA space. For mine the value of the company is the cholesterol program, and I’m just reassured to see they’re getting closer to this trial starting, that they redesigned it to see a efficacy signal in patients with high cholesterol. I mean would anyone really sell their shares based on the stroke study not having positive results?
NYR Price at posting:
8.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)